1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS
暂无分享,去创建一个
T. Pilot‐Matias | T. Marbury | W. Xie | E. Lawitz | B. Bernstein | T. Podsadecki | C. Setze | E. Dumas | A. Campbell | P. Krishnan | M. Kapoor | L. Williams | T. Pilot-matias | Preethi Krishnan